Meeting
2015 ASCO Annual Meeting
Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer.
Authors
Katsuhiko Nakatsukasa
Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
Katsuhiko Nakatsukasa , Tetsuya Taguchi , Riho Sugimoto , Kouichi Sakaguchi , Tatsuya Kotani , Kenichirou Hukuda , Sadao Kawakami , Ikuya Hujiwara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
UMIN000013263
Citation
J Clin Oncol 33, 2015 (suppl; abstr 583)
DOI
10.1200/jco.2015.33.15_suppl.583
Abstract #
583
Poster Bd #
72
Abstract Disclosures
Similar Posters
Poster
2015 Breast Cancer Symposium
Pathologic complete response after neoadjuvant paclitaxel and carboplatin chemotherapy for stage II-III breast cancer: A community cancer center experience.
First Author: Anuradha Belur
Poster
2015 ASCO Annual Meeting
Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial.
First Author: Debu Tripathy
Poster
2022 ASCO Annual Meeting
Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.
First Author: Alexandra Thomas
Poster
2018 ASCO Annual Meeting
A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).
First Author: Emanuela Risi